Adaptimmune TherapeuticsADAP
Market Cap: 355M
About: Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Employees: 449
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
206% more call options, than puts
Call options by funds: $379K | Put options by funds: $124K
125% more capital invested
Capital invested by funds: $114M [Q4 2023] → $256M (+$142M) [Q1 2024]
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
4% more funds holding
Funds holding: 77 [Q4 2023] → 80 (+3) [Q1 2024]
0.41% more ownership
Funds ownership: 10.54% [Q4 2023] → 10.94% (+0.41%) [Q1 2024]
26% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 23
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2023] → 1 (-1) [Q1 2024]
Research analyst outlook
2 Wall Street Analysts provided 1 year price forecasts over the past 6 months
2 analyst ratings
Scotiabank George Farmer | 127%upside $3.15 | Sector Outperform Initiated | 30 May 2024 |
Mizuho Graig Suvannavejh | 116%upside $3 | Buy Maintained | 17 May 2024 |